Molecular aspects of antitumor effects of a new platinum(IV) drug
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
16896071
DOI
10.1124/mol.106.027730
PII: S0026-895X(24)04224-X
Knihovny.cz E-zdroje
- MeSH
- adamantan analogy a deriváty terapeutické užití MeSH
- adukty DNA účinky léků MeSH
- bezbuněčný systém MeSH
- DNA řízené RNA-polymerasy metabolismus MeSH
- DNA biosyntéza MeSH
- HeLa buňky MeSH
- HIV-1 enzymologie MeSH
- krysa rodu Rattus MeSH
- kyselina askorbová metabolismus MeSH
- lidé MeSH
- molekulární sekvence - údaje MeSH
- nádorové buněčné linie MeSH
- nádory farmakoterapie MeSH
- oprava DNA genetika MeSH
- organoplatinové sloučeniny terapeutické užití MeSH
- platina metabolismus MeSH
- plazmidy genetika MeSH
- proteiny s vysokou pohyblivostí metabolismus MeSH
- protinádorové látky terapeutické užití MeSH
- reagencia zkříženě vázaná MeSH
- reverzní transkriptasa metabolismus MeSH
- sekvence nukleotidů MeSH
- sloučeniny síry metabolismus MeSH
- virové proteiny metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- (PtCl(2)(CH(3)COO)(2)-(NH(3))(1-adamantylamine)) MeSH Prohlížeč
- adamantan MeSH
- adukty DNA MeSH
- bacteriophage T7 RNA polymerase MeSH Prohlížeč
- DNA řízené RNA-polymerasy MeSH
- DNA MeSH
- kyselina askorbová MeSH
- organoplatinové sloučeniny MeSH
- platina MeSH
- proteiny s vysokou pohyblivostí MeSH
- protinádorové látky MeSH
- reagencia zkříženě vázaná MeSH
- reverzní transkriptasa MeSH
- sloučeniny síry MeSH
- virové proteiny MeSH
The new platinum(IV) complex cis,trans,cis-[PtCl(2)(CH(3)COO)(2)-(NH(3))(1-adamantylamine)] [adamplatin(IV)] seems promising for the perspective application in therapy of corresponding tumors. It is therefore of great interest to understand details of mechanisms underlying its biological efficacy. Cellular uptake of the drug, alterations in the target DNA induced by platinum drugs along with processing of platinum-induced damage to DNA and drug inactivation by sulfur-containing compounds belong to major pharmacological factors affecting antitumor effects of platinum compounds. We examined in the present work the significance of these factors in the mechanism of antitumor effects of adamplatin(IV) and compared the results with those of the parallel studies performed with "conventional" cisplatin. The results show that deactivation of adamplatin(IV) by sulfur-containing compounds (such as glutathione or metallothioneins) is likely to play a less significant role in the mechanism of resistance of tumor cells to adamplatin(IV) in contrast to the role of these reactions in the effects of cisplatin. Moreover, the treatment of tumor cells with adamplatin(IV) does not result in DNA modifications that would be markedly different from those produced by cisplatin. In contrast, the effects of other factors, such as enhanced accumulation of the drug in cells, strong inhibition of DNA polymerization by these adducts, lowered DNA repair, and DNA-protein cross-linking are different from the effects of these factors in the mechanism underlying activity of cisplatin. Hence, the differences between effects of adamplatin(IV) and cisplatin observed in the present work on molecular level may help understand the unique activity of adamplatin(IV).
Citace poskytuje Crossref.org